The role of long chain omega-3 polyunsaturated fatty acids (fish oil) on weight loss

Not Applicable

Recruiting

• Conditions: obesity; Diet and Nutrition - Obesity

• Registration Number: ACTRN12610000654055
• Lead Sponsor: The University of Newcastle

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-08-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Body Mass Index (BMI) between 30 and 40
Can consume fish
Can swallow capsules

Exclusion Criteria

BMI > 40; Diabetic; Already consuming fish oil caplsules or more than 2 oily fish meals/week; Has an inflammatory condition

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of % change in weight from baseline between groups using a calibrated balance beam scale to measure weight[At baseline, at 4 weeks and at 8 weeks, all within the treatment period];Comparison of % change in total body fat from baseline between groups using bioelectrical impedance[At baseline, at 4 weeks and at 8 weeks, all within the treatment period];Comparison of % change in fat free mass from baseline between groups using bioelectrical impedance[At baseline, at 4 weeks and at 8 weeks, all within the treatment period]

Secondary Outcome Measures

Name	Time	Method
Comparison of changes in blood glucose from baseline between groups. Fasting blood glucose will be analysed by Hunter Area Pathology Services[At baseline, at 4 weeks and at 8 weeks, all within the treatment period];Comparison of changes in plasma fatty acids which will be determined using gas chromatography analysis[At baseline, at 4 weeks and at 8 weeks, all within the treatment period];Comparison of changes in inflammatory biomarkers from baseline between groups using commercially available Enzyme Linked ImmunoSorbent Assays (ELISAs), namely, Leptin, Adiponectin, Interleukin-6 (IL-6), Tumour Necrosis Factors alpha (TNFa). Also C-reactive protein which will be analysed by Hunter Area Pathology Services[At baseline, at 4 weeks and at 8 weeks, all within the treatment period]